Literature DB >> 8878602

Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis.

R A Larsen1, M Bauer, J M Weiner, D M Diamond, M E Leal, J C Ding, M G Rinaldi, J R Graybill.   

Abstract

Both animal and in vitro studies have demonstrated that combinations of flucytosine with amphotericin B and with fluconazole have significantly improved activity against cryptococcal meningitis compared with the activity of each drug used alone. However, very few dose levels of these agents have been tested in combination. This study evaluated the efficacy of fluconazole plus flucytosine in a murine model of cryptococcal meningitis over a broad range of dose combinations (fluconazole, 0 to 40 micrograms/g of body weight per day; flucytosine, 0 to 200 micrograms/g/day). Both drugs were dissolved in drinking water, with treatment on days 2 to 11. In this highly reproducible model, fluconazole had a dramatic effect on the fungicidal activity of flucytosine. Flucytosine at dose levels of as much as 200 micrograms/g/day alone or in combination with low doses of fluconazole had minimal fungicidal activity, whereas in combination with fluconazole at 24 to 40 micrograms/g/day, flucytosine showed fungicidal activity in the range of 45 to 65% of the animals treated at doses of 40 to 100 micrograms/g/day. This striking effect of fluconazole is consistent with the results of both in vitro and clinical studies. In the clinic, the use of flucytosine is often limited by severe toxicity, while toxicity is rarely observed with fluconazole. These results suggest that when flucytosine is given with higher doses of fluconazole, the maximum therapeutic effect of the former in the clinic may be observed at dose levels that are far less than the doses commonly employed (150 micrograms/g daily).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878602      PMCID: PMC163494     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.

Authors:  M S Saag; W G Powderly; G A Cloud; P Robinson; M H Grieco; P K Sharkey; S E Thompson; A M Sugar; C U Tuazon; J F Fisher
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

2.  Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial.

Authors:  R A Larsen; M A Leal; L S Chan
Journal:  Ann Intern Med       Date:  1990-08-01       Impact factor: 25.391

3.  A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis.

Authors:  J E Bennett; W E Dismukes; R J Duma; G Medoff; M A Sande; H Gallis; J Leonard; B T Fields; M Bradshaw; H Haywood; Z A McGee; T R Cate; C G Cobbs; J F Warner; D W Alling
Journal:  N Engl J Med       Date:  1979-07-19       Impact factor: 91.245

4.  Confidence intervals for the survival function using Cox's proportional-hazard model with covariates.

Authors:  C L Link
Journal:  Biometrics       Date:  1984-09       Impact factor: 2.571

5.  Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis.

Authors:  R Allendoerfer; A J Marquis; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

6.  Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS.

Authors:  A J Berry; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

7.  Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.

Authors:  R A Larsen; S A Bozzette; B E Jones; D Haghighat; M A Leal; D Forthal; M Bauer; J G Tilles; J A McCutchan; J M Leedom
Journal:  Clin Infect Dis       Date:  1994-10       Impact factor: 9.079

8.  Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis.

Authors:  J D Velez; R Allendoerfer; M Luther; M G Rinaldi; J R Graybill
Journal:  J Infect Dis       Date:  1993-08       Impact factor: 5.226

9.  Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis.

Authors:  A M Stamm; R B Diasio; W E Dismukes; S Shadomy; G A Cloud; C A Bowles; G H Karam; A Espinel-Ingroff
Journal:  Am J Med       Date:  1987-08       Impact factor: 4.965

10.  In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans.

Authors:  M H Nguyen; F Barchiesi; D A McGough; V L Yu; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

  10 in total
  23 in total

1.  In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.

Authors:  Patrick Schwarz; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 2.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 3.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

4.  Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.

Authors:  Patrick Schwarz; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  Interactions of posaconazole and flucytosine against Cryptococcus neoformans.

Authors:  F Barchiesi; A M Schimizzi; L K Najvar; R Bocanegra; F Caselli; S Di Cesare; D Giannini; L F Di Francesco; A Giacometti; F Carle; G Scalise; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 6.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

7.  Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis.

Authors:  J C Ding; M Bauer; D M Diamond; M A Leal; D Johnson; B K Williams; A M Thomas; L Najvar; J R Graybill; R A Larsen
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 8.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

9.  Antitumor therapy mediated by 5-fluorocytosine and a recombinant fusion protein containing TSG-6 hyaluronan binding domain and yeast cytosine deaminase.

Authors:  Joshua I Park; Limin Cao; Virginia M Platt; Zhaohua Huang; Robert A Stull; Edward E Dy; Jeffrey J Sperinde; Jennifer S Yokoyama; Francis C Szoka
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

10.  New guinea pig model of Cryptococcal meningitis.

Authors:  William R Kirkpatrick; Laura K Najvar; Rosie Bocanegra; Thomas F Patterson; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.